#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Here , we describe a link between fructose and NO levels in the NTS , as well as its association with baroreflex sensitivity and activation of the CNS .
2-1	14-18	Here	_	_	_	_
2-2	19-20	,	_	_	_	_
2-3	21-23	we	person	acc	ana	3-1
2-4	24-32	describe	_	_	_	_
2-5	33-34	a	abstract[3]	new[3]	ana	2-19[0_3]
2-6	35-39	link	abstract[3]	new[3]	_	_
2-7	40-47	between	abstract[3]	new[3]	_	_
2-8	48-56	fructose	abstract[3]|substance	new[3]|new	coref	3-6
2-9	57-60	and	abstract[3]	new[3]	_	_
2-10	61-63	NO	abstract[3]|abstract[5]	new[3]|new[5]	coref	4-5[27_5]
2-11	64-70	levels	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-12	71-73	in	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-13	74-77	the	abstract[3]|abstract[5]|object[6]	new[3]|new[5]|new[6]	coref	26-13[203_6]
2-14	78-81	NTS	abstract[3]|abstract[5]|object[6]	new[3]|new[5]|new[6]	_	_
2-15	82-83	,	_	_	_	_
2-16	84-86	as	_	_	_	_
2-17	87-91	well	_	_	_	_
2-18	92-94	as	_	_	_	_
2-19	95-98	its	abstract|abstract[8]	giv|new[8]	coref	6-6[44_0]
2-20	99-110	association	abstract[8]	new[8]	_	_
2-21	111-115	with	abstract[8]	new[8]	_	_
2-22	116-126	baroreflex	abstract[8]|abstract[9]|abstract[10]	new[8]|new[9]|new[10]	coref|coref	21-3[159_9]|25-11[196_10]
2-23	127-138	sensitivity	abstract[8]|abstract[9]|abstract[10]	new[8]|new[9]|new[10]	_	_
2-24	139-142	and	abstract[8]|abstract[10]	new[8]|new[10]	_	_
2-25	143-153	activation	abstract[8]|abstract[10]|event[11]	new[8]|new[10]|new[11]	coref	4-24[33_11]
2-26	154-156	of	abstract[8]|abstract[10]|event[11]	new[8]|new[10]|new[11]	_	_
2-27	157-160	the	abstract[8]|abstract[10]|event[11]|abstract[12]	new[8]|new[10]|new[11]|new[12]	_	_
2-28	161-164	CNS	abstract[8]|abstract[10]|event[11]|abstract[12]	new[8]|new[10]|new[11]|new[12]	_	_
2-29	165-166	.	_	_	_	_

#Text=Our findings showed that excessive fructose consumption increased BP and renal SNA , decreased NO bioavailability , and impaired baroreflex response .
3-1	167-170	Our	person|abstract[14]	giv|new[14]	ana	17-7
3-2	171-179	findings	abstract[14]	new[14]	_	_
3-3	180-186	showed	_	_	_	_
3-4	187-191	that	_	_	_	_
3-5	192-201	excessive	abstract[16]	new[16]	coref	5-19[41_16]
3-6	202-210	fructose	abstract|abstract[16]	giv|new[16]	coref	4-2
3-7	211-222	consumption	abstract[16]	new[16]	_	_
3-8	223-232	increased	abstract	new	none|none	3-8[0_107]|4-4
3-9	233-235	BP	organization	new	coref	4-10
3-10	236-239	and	_	_	_	_
3-11	240-245	renal	abstract|abstract[19]	new|new[19]	coref	4-14[0_19]
3-12	246-249	SNA	abstract[19]	new[19]	_	_
3-13	250-251	,	_	_	_	_
3-14	252-261	decreased	_	_	_	_
3-15	262-264	NO	abstract[20]	new[20]	_	_
3-16	265-280	bioavailability	abstract[20]	new[20]	_	_
3-17	281-282	,	_	_	_	_
3-18	283-286	and	_	_	_	_
3-19	287-295	impaired	_	_	_	_
3-20	296-306	baroreflex	object|abstract[22]	new|new[22]	coref	20-2
3-21	307-315	response	abstract[22]	new[22]	_	_
3-22	316-317	.	_	_	_	_

#Text=Excessive fructose intake increased serum triglycerides levels and induced BP elevation by stimulating SNA ; however , alleviation of hypertriglyceridemia did not attenuate sympathetic activation and only slightly lowered BP .
4-1	318-327	Excessive	event[24]	new[24]	coref	7-16[63_24]
4-2	328-336	fructose	substance|event[24]	giv|new[24]	coref	5-20
4-3	337-343	intake	event[24]	new[24]	_	_
4-4	344-353	increased	abstract	new	none	7-11
4-5	354-359	serum	abstract|abstract[27]	new|giv[27]	coref|coref	11-16[101_27]|14-28
4-6	360-373	triglycerides	substance|abstract[27]	new|giv[27]	coref	24-17
4-7	374-380	levels	abstract[27]	giv[27]	_	_
4-8	381-384	and	abstract[27]	giv[27]	_	_
4-9	385-392	induced	abstract[27]|abstract[29]	giv[27]|new[29]	_	_
4-10	393-395	BP	abstract[27]|organization|abstract[29]	giv[27]|giv|new[29]	coref	4-27[34_0]
4-11	396-405	elevation	abstract[27]|abstract[29]	giv[27]|new[29]	_	_
4-12	406-408	by	_	_	_	_
4-13	409-420	stimulating	_	_	_	_
4-14	421-424	SNA	abstract	giv	coref	5-8
4-15	425-426	;	_	_	_	_
4-16	427-434	however	_	_	_	_
4-17	435-436	,	_	_	_	_
4-18	437-448	alleviation	event[31]	new[31]	_	_
4-19	449-451	of	event[31]	new[31]	_	_
4-20	452-472	hypertriglyceridemia	event[31]|abstract	new[31]|new	ana	5-1
4-21	473-476	did	_	_	_	_
4-22	477-480	not	_	_	_	_
4-23	481-490	attenuate	_	_	_	_
4-24	491-502	sympathetic	event[33]	giv[33]	_	_
4-25	503-513	activation	event[33]	giv[33]	_	_
4-26	514-517	and	_	_	_	_
4-27	518-522	only	organization[34]	giv[34]	coref	5-16[39_34]
4-28	523-531	slightly	organization[34]	giv[34]	_	_
4-29	532-539	lowered	organization[34]	giv[34]	_	_
4-30	540-542	BP	organization[34]	giv[34]	_	_
4-31	543-544	.	_	_	_	_

#Text=It was suggested that , mechanistically , SNA played a role in modulating changes in BP due to increased fructose consumption through another unknown pathway .
5-1	545-547	It	abstract	giv	coref	9-12
5-2	548-551	was	_	_	_	_
5-3	552-561	suggested	_	_	_	_
5-4	562-566	that	_	_	_	_
5-5	567-568	,	_	_	_	_
5-6	569-584	mechanistically	_	_	_	_
5-7	585-586	,	_	_	_	_
5-8	587-590	SNA	abstract	giv	coref	14-44[121_0]
5-9	591-597	played	_	_	_	_
5-10	598-599	a	abstract[37]	new[37]	_	_
5-11	600-604	role	abstract[37]	new[37]	_	_
5-12	605-607	in	_	_	_	_
5-13	608-618	modulating	_	_	_	_
5-14	619-626	changes	abstract	new	_	_
5-15	627-629	in	_	_	_	_
5-16	630-632	BP	organization[39]	giv[39]	coref	6-38[0_39]
5-17	633-636	due	organization[39]	giv[39]	_	_
5-18	637-639	to	_	_	_	_
5-19	640-649	increased	abstract[41]	giv[41]	coref	6-9[46_41]
5-20	650-658	fructose	abstract|abstract[41]	giv|giv[41]	coref	6-9
5-21	659-670	consumption	abstract[41]	giv[41]	_	_
5-22	671-678	through	abstract[41]	giv[41]	_	_
5-23	679-686	another	abstract[41]|abstract[42]	giv[41]|new[42]	_	_
5-24	687-694	unknown	abstract[41]|abstract[42]	giv[41]|new[42]	_	_
5-25	695-702	pathway	abstract[41]|abstract[42]	giv[41]|new[42]	_	_
5-26	703-704	.	_	_	_	_

#Text=Epidemiological studies have hinted at a link between fructose consumption and elevated blood pressure . Jalal et al. reported that excess dietary fructose ( ≥74 g/day ) in the form of added sugar was associated with higher BP values in adults in the United States who did not have a history of hypertension .
6-1	705-720	Epidemiological	abstract[43]	new[43]	coref	9-1[81_43]
6-2	721-728	studies	abstract[43]	new[43]	_	_
6-3	729-733	have	_	_	_	_
6-4	734-740	hinted	_	_	_	_
6-5	741-743	at	_	_	_	_
6-6	744-745	a	abstract[44]	giv[44]	_	_
6-7	746-750	link	abstract[44]	giv[44]	_	_
6-8	751-758	between	abstract[44]	giv[44]	_	_
6-9	759-767	fructose	abstract[44]|substance|abstract[46]	giv[44]|giv|giv[46]	coref|coref	4-4|14-5[109_46]
6-10	768-779	consumption	abstract[44]|abstract[46]	giv[44]|giv[46]	_	_
6-11	780-783	and	abstract[44]	giv[44]	_	_
6-12	784-792	elevated	abstract[44]|abstract[47]	giv[44]|new[47]	_	_
6-13	793-798	blood	abstract[44]|abstract[47]	giv[44]|new[47]	_	_
6-14	799-807	pressure	abstract[44]|abstract[47]	giv[44]|new[47]	_	_
6-15	808-809	.	_	_	_	_
6-16	810-815	Jalal	person	new	_	_
6-17	816-818	et	_	_	_	_
6-18	819-822	al.	_	_	_	_
6-19	823-831	reported	_	_	_	_
6-20	832-836	that	_	_	_	_
6-21	837-843	excess	substance[50]	giv[50]	coref	11-6
6-22	844-851	dietary	abstract|substance[50]	new|giv[50]	_	_
6-23	852-860	fructose	substance[50]	giv[50]	_	_
6-24	861-862	(	_	_	_	_
6-25	863-866	≥74	_	_	_	_
6-26	867-872	g/day	_	_	_	_
6-27	873-874	)	_	_	_	_
6-28	875-877	in	_	_	_	_
6-29	878-881	the	substance[51]	new[51]	_	_
6-30	882-886	form	substance[51]	new[51]	_	_
6-31	887-889	of	substance[51]	new[51]	_	_
6-32	890-895	added	substance[51]|substance[52]	new[51]|new[52]	_	_
6-33	896-901	sugar	substance[51]|substance[52]	new[51]|new[52]	_	_
6-34	902-905	was	_	_	_	_
6-35	906-916	associated	_	_	_	_
6-36	917-921	with	_	_	_	_
6-37	922-928	higher	abstract[54]	new[54]	_	_
6-38	929-931	BP	organization|abstract[54]	giv|new[54]	coref	9-25
6-39	932-938	values	abstract[54]	new[54]	_	_
6-40	939-941	in	abstract[54]	new[54]	_	_
6-41	942-948	adults	abstract[54]|person[55]	new[54]|new[55]	coref	8-6[67_55]
6-42	949-951	in	abstract[54]|person[55]	new[54]|new[55]	_	_
6-43	952-955	the	abstract[54]|person[55]|place[56]	new[54]|new[55]|new[56]	coref	8-8[68_56]
6-44	956-962	United	abstract[54]|person[55]|place[56]	new[54]|new[55]|new[56]	_	_
6-45	963-969	States	abstract[54]|person[55]|place[56]	new[54]|new[55]|new[56]	_	_
6-46	970-973	who	_	_	_	_
6-47	974-977	did	_	_	_	_
6-48	978-981	not	_	_	_	_
6-49	982-986	have	_	_	_	_
6-50	987-988	a	abstract[57]	new[57]	_	_
6-51	989-996	history	abstract[57]	new[57]	_	_
6-52	997-999	of	abstract[57]	new[57]	_	_
6-53	1000-1012	hypertension	abstract[57]|abstract	new[57]|new	coref	15-7
6-54	1013-1014	.	_	_	_	_

#Text=Similarly , a study of 4867 adolescents found that SBP rose by 2 mmHg following the intake of sugar-sweetened beverages from the lowest to the highest category .
7-1	1015-1024	Similarly	_	_	_	_
7-2	1025-1026	,	_	_	_	_
7-3	1027-1028	a	event[59]	new[59]	coref	8-2[66_59]
7-4	1029-1034	study	event[59]	new[59]	_	_
7-5	1035-1037	of	event[59]	new[59]	_	_
7-6	1038-1042	4867	event[59]|quantity[60]	new[59]|new[60]	_	_
7-7	1043-1054	adolescents	event[59]|quantity[60]	new[59]|new[60]	_	_
7-8	1055-1060	found	_	_	_	_
7-9	1061-1065	that	_	_	_	_
7-10	1066-1069	SBP	quantity	new	coref	8-33
7-11	1070-1074	rose	abstract	new	none	9-24
7-12	1075-1077	by	_	_	_	_
7-13	1078-1079	2	quantity[62]	new[62]	_	_
7-14	1080-1084	mmHg	quantity[62]	new[62]	_	_
7-15	1085-1094	following	_	_	_	_
7-16	1095-1098	the	event[63]	giv[63]	_	_
7-17	1099-1105	intake	event[63]	giv[63]	_	_
7-18	1106-1108	of	event[63]	giv[63]	_	_
7-19	1109-1124	sugar-sweetened	event[63]|substance[64]	giv[63]|new[64]	_	_
7-20	1125-1134	beverages	event[63]|substance[64]	giv[63]|new[64]	_	_
7-21	1135-1139	from	event[63]|substance[64]	giv[63]|new[64]	_	_
7-22	1140-1143	the	event[63]|substance[64]	giv[63]|new[64]	_	_
7-23	1144-1150	lowest	event[63]|substance[64]	giv[63]|new[64]	_	_
7-24	1151-1153	to	_	_	_	_
7-25	1154-1157	the	abstract[65]	new[65]	_	_
7-26	1158-1165	highest	abstract[65]	new[65]	_	_
7-27	1166-1174	category	abstract[65]	new[65]	_	_
7-28	1175-1176	.	_	_	_	_

#Text=In a prospective study involving adults in the United States , Chen et al. found that intake of one less sugar-sweetened beverage per day was associated with a 1.8 mmHg reduction in SBP and a 1.1 mmHg reduction in DBP over 18 months .
8-1	1177-1179	In	_	_	_	_
8-2	1180-1181	a	event[66]	giv[66]	coref	11-2[95_66]
8-3	1182-1193	prospective	event[66]	giv[66]	_	_
8-4	1194-1199	study	event[66]	giv[66]	_	_
8-5	1200-1209	involving	event[66]	giv[66]	_	_
8-6	1210-1216	adults	event[66]|person[67]	giv[66]|giv[67]	_	_
8-7	1217-1219	in	event[66]|person[67]	giv[66]|giv[67]	_	_
8-8	1220-1223	the	event[66]|person[67]|place[68]	giv[66]|giv[67]|giv[68]	_	_
8-9	1224-1230	United	event[66]|person[67]|place[68]	giv[66]|giv[67]|giv[68]	_	_
8-10	1231-1237	States	event[66]|person[67]|place[68]	giv[66]|giv[67]|giv[68]	_	_
8-11	1238-1239	,	_	_	_	_
8-12	1240-1244	Chen	person	new	_	_
8-13	1245-1247	et	_	_	_	_
8-14	1248-1251	al.	_	_	_	_
8-15	1252-1257	found	_	_	_	_
8-16	1258-1262	that	event[70]	new[70]	coref	11-6[97_70]
8-17	1263-1269	intake	event[70]	new[70]	_	_
8-18	1270-1272	of	event[70]	new[70]	_	_
8-19	1273-1276	one	event[70]|substance[71]	new[70]|new[71]	_	_
8-20	1277-1281	less	event[70]|substance[71]	new[70]|new[71]	_	_
8-21	1282-1297	sugar-sweetened	event[70]|substance[71]	new[70]|new[71]	_	_
8-22	1298-1306	beverage	event[70]|substance[71]	new[70]|new[71]	_	_
8-23	1307-1310	per	event[70]|substance[71]	new[70]|new[71]	_	_
8-24	1311-1314	day	event[70]|substance[71]|time	new[70]|new[71]|new	coref	11-27
8-25	1315-1318	was	_	_	_	_
8-26	1319-1329	associated	_	_	_	_
8-27	1330-1334	with	_	_	_	_
8-28	1335-1336	a	abstract[74]	new[74]	_	_
8-29	1337-1340	1.8	abstract[74]	new[74]	_	_
8-30	1341-1345	mmHg	quantity|abstract[74]	new|new[74]	coref	8-37
8-31	1346-1355	reduction	abstract[74]	new[74]	_	_
8-32	1356-1358	in	abstract[74]	new[74]	_	_
8-33	1359-1362	SBP	abstract[74]|quantity	new[74]|giv	_	_
8-34	1363-1366	and	_	_	_	_
8-35	1367-1368	a	abstract[77]	new[77]	_	_
8-36	1369-1372	1.1	abstract[77]	new[77]	_	_
8-37	1373-1377	mmHg	quantity|abstract[77]	giv|new[77]	_	_
8-38	1378-1387	reduction	abstract[77]	new[77]	_	_
8-39	1388-1390	in	abstract[77]	new[77]	_	_
8-40	1391-1394	DBP	abstract[77]|abstract	new[77]|new	_	_
8-41	1395-1399	over	abstract[77]|time[79]	new[77]|new[79]	_	_
8-42	1400-1402	18	abstract[77]|time[79]	new[77]|new[79]	_	_
8-43	1403-1409	months	abstract[77]|time[79]	new[77]|new[79]	_	_
8-44	1410-1411	.	_	_	_	_

#Text=Some animal studies showed that a high-fructose diet was associated with hypertriglyceridemia , hyperinsulinemia , impaired glucose tolerance , insulin resistance , and increased BP and body weight .
9-1	1412-1416	Some	abstract[81]	giv[81]	_	_
9-2	1417-1423	animal	animal|abstract[81]	new|giv[81]	_	_
9-3	1424-1431	studies	abstract[81]	giv[81]	_	_
9-4	1432-1438	showed	_	_	_	_
9-5	1439-1443	that	_	_	_	_
9-6	1444-1445	a	abstract[82]	new[82]	_	_
9-7	1446-1459	high-fructose	abstract[82]	new[82]	_	_
9-8	1460-1464	diet	abstract[82]	new[82]	_	_
9-9	1465-1468	was	_	_	_	_
9-10	1469-1479	associated	_	_	_	_
9-11	1480-1484	with	_	_	_	_
9-12	1485-1505	hypertriglyceridemia	abstract	giv	coref	22-6
9-13	1506-1507	,	_	_	_	_
9-14	1508-1524	hyperinsulinemia	abstract	new	_	_
9-15	1525-1526	,	_	_	_	_
9-16	1527-1535	impaired	abstract[86]	new[86]	_	_
9-17	1536-1543	glucose	substance|abstract[86]	new|new[86]	coref	10-13
9-18	1544-1553	tolerance	abstract[86]	new[86]	_	_
9-19	1554-1555	,	_	_	_	_
9-20	1556-1563	insulin	event|abstract[88]	new|new[88]	_	_
9-21	1564-1574	resistance	abstract[88]	new[88]	_	_
9-22	1575-1576	,	_	_	_	_
9-23	1577-1580	and	_	_	_	_
9-24	1581-1590	increased	abstract	new	none	11-5
9-25	1591-1593	BP	organization	giv	coref	11-16
9-26	1594-1597	and	_	_	_	_
9-27	1598-1602	body	object|abstract[91]	new|new[91]	_	_
9-28	1603-1609	weight	abstract[91]	new[91]	_	_
9-29	1610-1611	.	_	_	_	_

#Text=However , these adverse effects were not indicated with equivalent calories of glucose .
10-1	1612-1619	However	_	_	_	_
10-2	1620-1621	,	_	_	_	_
10-3	1622-1627	these	abstract[92]	new[92]	coref	21-11[162_92]
10-4	1628-1635	adverse	abstract[92]	new[92]	_	_
10-5	1636-1643	effects	abstract[92]	new[92]	_	_
10-6	1644-1648	were	_	_	_	_
10-7	1649-1652	not	_	_	_	_
10-8	1653-1662	indicated	_	_	_	_
10-9	1663-1667	with	_	_	_	_
10-10	1668-1678	equivalent	substance[93]	new[93]	_	_
10-11	1679-1687	calories	substance[93]	new[93]	_	_
10-12	1688-1690	of	substance[93]	new[93]	_	_
10-13	1691-1698	glucose	substance[93]|substance	new[93]|giv	_	_
10-14	1699-1700	.	_	_	_	_

#Text=In this study , increased fructose intake for 0 to 2 days evoked increases in BP levels , and the high BP levels were maintained until day 7 (
11-1	1701-1703	In	_	_	_	_
11-2	1704-1708	this	event[95]	giv[95]	coref	22-1[165_95]
11-3	1709-1714	study	event[95]	giv[95]	_	_
11-4	1715-1716	,	_	_	_	_
11-5	1717-1726	increased	abstract	new	coref	14-1[107_0]
11-6	1727-1735	fructose	substance|event[97]	giv|giv[97]	coref|coref	14-5|26-6[201_97]
11-7	1736-1742	intake	event[97]	giv[97]	_	_
11-8	1743-1746	for	_	_	_	_
11-9	1747-1748	0	time[98]	new[98]	_	_
11-10	1749-1751	to	time[98]	new[98]	_	_
11-11	1752-1753	2	time[98]	new[98]	_	_
11-12	1754-1758	days	time[98]	new[98]	_	_
11-13	1759-1765	evoked	_	_	_	_
11-14	1766-1775	increases	event[99]	new[99]	_	_
11-15	1776-1778	in	event[99]	new[99]	_	_
11-16	1779-1781	BP	event[99]|organization|abstract[101]	new[99]|giv|giv[101]	coref|coref	11-22|11-20[103_101]
11-17	1782-1788	levels	event[99]|abstract[101]	new[99]|giv[101]	_	_
11-18	1789-1790	,	_	_	_	_
11-19	1791-1794	and	_	_	_	_
11-20	1795-1798	the	abstract[103]	giv[103]	coref	14-31[119_103]
11-21	1799-1803	high	abstract[103]	giv[103]	_	_
11-22	1804-1806	BP	organization|abstract[103]	giv|giv[103]	coref	17-28
11-23	1807-1813	levels	abstract[103]	giv[103]	_	_
11-24	1814-1818	were	_	_	_	_
11-25	1819-1829	maintained	_	_	_	_
11-26	1830-1835	until	_	_	_	_
11-27	1836-1839	day	time|time[105]	giv|new[105]	_	_
11-28	1840-1841	7	time[105]	new[105]	_	_
11-29	1842-1843	(	_	_	_	_

#Text=Figure 2
12-1	1844-1850	Figure	abstract[106]	new[106]	_	_
12-2	1851-1852	2	abstract[106]	new[106]	_	_

#Text=) .
13-1	1853-1854	)	_	_	_	_
13-2	1855-1856	.	_	_	_	_

#Text=The great increase in fructose consumption in the last decades leads to the rapid accumulation of triglyceride in the Occidental population . Tran et al. reported that serum norepinephrine and triglyceride levels are significantly increased in fructose-fed hypertensive rats , as reflected by high SNA .
14-1	1857-1860	The	abstract[107]	new[107]	_	_
14-2	1861-1866	great	abstract[107]	new[107]	_	_
14-3	1867-1875	increase	abstract[107]	new[107]	_	_
14-4	1876-1878	in	abstract[107]	new[107]	_	_
14-5	1879-1887	fructose	abstract[107]|substance|abstract[109]	new[107]|giv|giv[109]	coref|coref	15-15|15-14[126_109]
14-6	1888-1899	consumption	abstract[107]|abstract[109]	new[107]|giv[109]	_	_
14-7	1900-1902	in	abstract[107]|abstract[109]	new[107]|giv[109]	_	_
14-8	1903-1906	the	abstract[107]|abstract[109]|time[110]	new[107]|giv[109]|new[110]	_	_
14-9	1907-1911	last	abstract[107]|abstract[109]|time[110]	new[107]|giv[109]|new[110]	_	_
14-10	1912-1919	decades	abstract[107]|abstract[109]|time[110]	new[107]|giv[109]|new[110]	_	_
14-11	1920-1925	leads	_	_	_	_
14-12	1926-1928	to	_	_	_	_
14-13	1929-1932	the	abstract[111]	new[111]	_	_
14-14	1933-1938	rapid	abstract[111]	new[111]	_	_
14-15	1939-1951	accumulation	abstract[111]	new[111]	_	_
14-16	1952-1954	of	abstract[111]	new[111]	_	_
14-17	1955-1967	triglyceride	abstract[111]|substance[112]	new[111]|new[112]	coref	14-31[0_112]
14-18	1968-1970	in	abstract[111]|substance[112]	new[111]|new[112]	_	_
14-19	1971-1974	the	abstract[111]|substance[112]|abstract[114]	new[111]|new[112]|new[114]	_	_
14-20	1975-1985	Occidental	abstract[111]|substance[112]|organization|abstract[114]	new[111]|new[112]|new|new[114]	_	_
14-21	1986-1996	population	abstract[111]|substance[112]|abstract[114]	new[111]|new[112]|new[114]	_	_
14-22	1997-1998	.	_	_	_	_
14-23	1999-2003	Tran	person	new	coref	15-3
14-24	2004-2006	et	_	_	_	_
14-25	2007-2010	al.	_	_	_	_
14-26	2011-2019	reported	_	_	_	_
14-27	2020-2024	that	_	_	_	_
14-28	2025-2030	serum	abstract|substance[117]	giv|new[117]	coref	16-13
14-29	2031-2045	norepinephrine	substance[117]	new[117]	_	_
14-30	2046-2049	and	_	_	_	_
14-31	2050-2062	triglyceride	substance|abstract[119]	giv|giv[119]	coref|coref	16-11[135_0]|26-10[202_119]
14-32	2063-2069	levels	abstract[119]	giv[119]	_	_
14-33	2070-2073	are	_	_	_	_
14-34	2074-2087	significantly	_	_	_	_
14-35	2088-2097	increased	_	_	_	_
14-36	2098-2100	in	_	_	_	_
14-37	2101-2113	fructose-fed	animal[120]	new[120]	coref	15-11[0_120]
14-38	2114-2126	hypertensive	animal[120]	new[120]	_	_
14-39	2127-2131	rats	animal[120]	new[120]	_	_
14-40	2132-2133	,	_	_	_	_
14-41	2134-2136	as	_	_	_	_
14-42	2137-2146	reflected	_	_	_	_
14-43	2147-2149	by	_	_	_	_
14-44	2150-2154	high	abstract[121]	giv[121]	coref	17-33[0_121]
14-45	2155-2158	SNA	abstract[121]	giv[121]	_	_
14-46	2159-2160	.	_	_	_	_

#Text=According to Tran et al. , hypertension can develop in rats owing to excessive fructose consumption , and the developed hypertension can be treated using a sympatholytic agent called prazosin , which blocks the α1-adrenoreceptors .
15-1	2161-2170	According	_	_	_	_
15-2	2171-2173	to	_	_	_	_
15-3	2174-2178	Tran	person	giv	_	_
15-4	2179-2181	et	_	_	_	_
15-5	2182-2185	al.	_	_	_	_
15-6	2186-2187	,	_	_	_	_
15-7	2188-2200	hypertension	abstract	giv	coref	15-19[127_0]
15-8	2201-2204	can	_	_	_	_
15-9	2205-2212	develop	event	new	coref|none	26-26[207_0]|15-9[0_207]
15-10	2213-2215	in	_	_	_	_
15-11	2216-2220	rats	animal	giv	coref	22-37[176_0]
15-12	2221-2226	owing	_	_	_	_
15-13	2227-2229	to	_	_	_	_
15-14	2230-2239	excessive	abstract[126]	giv[126]	coref	25-7[194_126]
15-15	2240-2248	fructose	substance|abstract[126]	giv|giv[126]	coref	23-9
15-16	2249-2260	consumption	abstract[126]	giv[126]	_	_
15-17	2261-2262	,	_	_	_	_
15-18	2263-2266	and	_	_	_	_
15-19	2267-2270	the	abstract[127]	giv[127]	coref	16-1[0_127]
15-20	2271-2280	developed	abstract[127]	giv[127]	_	_
15-21	2281-2293	hypertension	abstract[127]	giv[127]	_	_
15-22	2294-2297	can	_	_	_	_
15-23	2298-2300	be	_	_	_	_
15-24	2301-2308	treated	_	_	_	_
15-25	2309-2314	using	_	_	_	_
15-26	2315-2316	a	person[128]	new[128]	_	_
15-27	2317-2330	sympatholytic	person[128]	new[128]	_	_
15-28	2331-2336	agent	person[128]	new[128]	_	_
15-29	2337-2343	called	_	_	_	_
15-30	2344-2352	prazosin	substance	new	coref	16-4
15-31	2353-2354	,	_	_	_	_
15-32	2355-2360	which	_	_	_	_
15-33	2361-2367	blocks	_	_	_	_
15-34	2368-2371	the	abstract[130]	new[130]	_	_
15-35	2372-2390	α1-adrenoreceptors	abstract[130]	new[130]	_	_
15-36	2391-2392	.	_	_	_	_

#Text=Hypertension inhibition by prazosin did not reduce the level of triglyceride in serum .
16-1	2393-2405	Hypertension	abstract|abstract[132]	giv|new[132]	_	_
16-2	2406-2416	inhibition	abstract[132]	new[132]	_	_
16-3	2417-2419	by	abstract[132]	new[132]	_	_
16-4	2420-2428	prazosin	abstract[132]|substance	new[132]|giv	_	_
16-5	2429-2432	did	_	_	_	_
16-6	2433-2436	not	_	_	_	_
16-7	2437-2443	reduce	_	_	_	_
16-8	2444-2447	the	abstract[134]	new[134]	coref	17-19[145_134]
16-9	2448-2453	level	abstract[134]	new[134]	_	_
16-10	2454-2456	of	abstract[134]	new[134]	_	_
16-11	2457-2469	triglyceride	abstract[134]|substance[135]	new[134]|giv[135]	coref	17-20[0_135]
16-12	2470-2472	in	abstract[134]|substance[135]	new[134]|giv[135]	_	_
16-13	2473-2478	serum	abstract[134]|substance[135]|substance	new[134]|giv[135]|giv	coref	17-19
16-14	2479-2480	.	_	_	_	_

#Text=Consistent with this previous result , our data showed that the use of a DGAT1 inhibitor for inhibiting serum triglyceride level led to a slight decrease in BP but did not affect SNA (
17-1	2481-2491	Consistent	_	_	_	_
17-2	2492-2496	with	_	_	_	_
17-3	2497-2501	this	abstract[137]	new[137]	_	_
17-4	2502-2510	previous	abstract[137]	new[137]	_	_
17-5	2511-2517	result	abstract[137]	new[137]	_	_
17-6	2518-2519	,	_	_	_	_
17-7	2520-2523	our	person|abstract[139]	giv|new[139]	ana	26-1
17-8	2524-2528	data	abstract[139]	new[139]	_	_
17-9	2529-2535	showed	_	_	_	_
17-10	2536-2540	that	_	_	_	_
17-11	2541-2544	the	abstract[140]	new[140]	_	_
17-12	2545-2548	use	abstract[140]	new[140]	_	_
17-13	2549-2551	of	abstract[140]	new[140]	_	_
17-14	2552-2553	a	abstract[140]|abstract[142]	new[140]|new[142]	coref	24-9[187_142]
17-15	2554-2559	DGAT1	abstract[140]|abstract|abstract[142]	new[140]|new|new[142]	coref	24-10
17-16	2560-2569	inhibitor	abstract[140]|abstract[142]	new[140]|new[142]	_	_
17-17	2570-2573	for	_	_	_	_
17-18	2574-2584	inhibiting	_	_	_	_
17-19	2585-2590	serum	object|abstract[145]	giv|giv[145]	coref	31-74[235_145]
17-20	2591-2603	triglyceride	substance|abstract[145]	giv|giv[145]	_	_
17-21	2604-2609	level	abstract[145]	giv[145]	_	_
17-22	2610-2613	led	_	_	_	_
17-23	2614-2616	to	_	_	_	_
17-24	2617-2618	a	abstract[146]	new[146]	_	_
17-25	2619-2625	slight	abstract[146]	new[146]	_	_
17-26	2626-2634	decrease	abstract[146]	new[146]	_	_
17-27	2635-2637	in	abstract[146]	new[146]	_	_
17-28	2638-2640	BP	abstract[146]|organization	new[146]|giv	coref	20-19[157_0]
17-29	2641-2644	but	_	_	_	_
17-30	2645-2648	did	_	_	_	_
17-31	2649-2652	not	_	_	_	_
17-32	2653-2659	affect	_	_	_	_
17-33	2660-2663	SNA	abstract	giv	coref	23-21[184_0]
17-34	2664-2665	(	_	_	_	_

#Text=Figure 3
18-1	2666-2672	Figure	abstract[149]	new[149]	_	_
18-2	2673-2674	3	abstract[149]	new[149]	_	_

#Text=) .
19-1	2675-2676	)	_	_	_	_
19-2	2677-2678	.	_	_	_	_

#Text=The baroreflex system is an important mechanism in the regulation of heart rate , sympathetic tone , and consequently BP .
20-1	2679-2682	The	place[151]	new[151]	coref	20-5[152_151]
20-2	2683-2693	baroreflex	place|place[151]	giv|new[151]	coref	26-17
20-3	2694-2700	system	place[151]	new[151]	_	_
20-4	2701-2703	is	_	_	_	_
20-5	2704-2706	an	place[152]	giv[152]	coref	32-16[243_152]
20-6	2707-2716	important	place[152]	giv[152]	_	_
20-7	2717-2726	mechanism	place[152]	giv[152]	_	_
20-8	2727-2729	in	place[152]	giv[152]	_	_
20-9	2730-2733	the	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-10	2734-2744	regulation	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-11	2745-2747	of	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-12	2748-2753	heart	place[152]|abstract[153]|abstract|abstract[155]	giv[152]|new[153]|new|new[155]	_	_
20-13	2754-2758	rate	place[152]|abstract[153]|abstract[155]	giv[152]|new[153]|new[155]	_	_
20-14	2759-2760	,	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-15	2761-2772	sympathetic	place[152]|abstract[153]|abstract[156]	giv[152]|new[153]|new[156]	_	_
20-16	2773-2777	tone	place[152]|abstract[153]|abstract[156]	giv[152]|new[153]|new[156]	_	_
20-17	2778-2779	,	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-18	2780-2783	and	place[152]|abstract[153]	giv[152]|new[153]	_	_
20-19	2784-2796	consequently	place[152]|abstract[153]|organization[157]	giv[152]|new[153]|giv[157]	coref	22-28[173_157]
20-20	2797-2799	BP	place[152]|abstract[153]|organization[157]	giv[152]|new[153]|giv[157]	_	_
20-21	2800-2801	.	_	_	_	_

#Text=Impairment of baroreflex sensitivity is involved in the sympathoexcitatory and sympathoinhibitory effects of metabolic syndromes .
21-1	2802-2812	Impairment	abstract[158]	new[158]	_	_
21-2	2813-2815	of	abstract[158]	new[158]	_	_
21-3	2816-2826	baroreflex	abstract[158]|abstract[159]	new[158]|giv[159]	coref	22-15[169_159]
21-4	2827-2838	sensitivity	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
21-5	2839-2841	is	_	_	_	_
21-6	2842-2850	involved	_	_	_	_
21-7	2851-2853	in	_	_	_	_
21-8	2854-2857	the	abstract[160]	new[160]	_	_
21-9	2858-2876	sympathoexcitatory	abstract[160]	new[160]	_	_
21-10	2877-2880	and	_	_	_	_
21-11	2881-2899	sympathoinhibitory	abstract|abstract[162]	new|giv[162]	_	_
21-12	2900-2907	effects	abstract[162]	giv[162]	_	_
21-13	2908-2910	of	abstract[162]	giv[162]	_	_
21-14	2911-2920	metabolic	abstract[162]|person|abstract[164]	giv[162]|new|new[164]	coref	22-20
21-15	2921-2930	syndromes	abstract[162]|abstract[164]	giv[162]|new[164]	_	_
21-16	2931-2932	.	_	_	_	_

#Text=A previous study showed that hypertriglyceridemia may be the main contributory factor associated with impaired baroreflex sensitivity during a metabolic syndrome . Soncrant et al. reported that elevated BP was increased by sympathoexcitation in 20 % fructose-induced , salt-sensitive , hypertensive rats .
22-1	2933-2934	A	event[165]	giv[165]	coref	24-4[185_165]
22-2	2935-2943	previous	event[165]	giv[165]	_	_
22-3	2944-2949	study	event[165]	giv[165]	_	_
22-4	2950-2956	showed	_	_	_	_
22-5	2957-2961	that	_	_	_	_
22-6	2962-2982	hypertriglyceridemia	abstract	giv	coref	22-9[168_0]
22-7	2983-2986	may	_	_	_	_
22-8	2987-2989	be	_	_	_	_
22-9	2990-2993	the	abstract[168]	giv[168]	_	_
22-10	2994-2998	main	abstract[168]	giv[168]	_	_
22-11	2999-3011	contributory	abstract|abstract[168]	new|giv[168]	_	_
22-12	3012-3018	factor	abstract[168]	giv[168]	_	_
22-13	3019-3029	associated	_	_	_	_
22-14	3030-3034	with	_	_	_	_
22-15	3035-3043	impaired	abstract[169]	giv[169]	coref	25-11[195_169]
22-16	3044-3054	baroreflex	abstract[169]	giv[169]	_	_
22-17	3055-3066	sensitivity	abstract[169]	giv[169]	_	_
22-18	3067-3073	during	abstract[169]	giv[169]	_	_
22-19	3074-3075	a	abstract[169]|event[171]	giv[169]|new[171]	_	_
22-20	3076-3085	metabolic	abstract[169]|person|event[171]	giv[169]|giv|new[171]	_	_
22-21	3086-3094	syndrome	abstract[169]|event[171]	giv[169]|new[171]	_	_
22-22	3095-3096	.	_	_	_	_
22-23	3097-3105	Soncrant	person	new	_	_
22-24	3106-3108	et	_	_	_	_
22-25	3109-3112	al.	_	_	_	_
22-26	3113-3121	reported	_	_	_	_
22-27	3122-3126	that	_	_	_	_
22-28	3127-3135	elevated	organization[173]	giv[173]	coref	26-29[208_173]
22-29	3136-3138	BP	organization[173]	giv[173]	_	_
22-30	3139-3142	was	_	_	_	_
22-31	3143-3152	increased	_	_	_	_
22-32	3153-3155	by	_	_	_	_
22-33	3156-3174	sympathoexcitation	abstract[174]	new[174]	coref	24-20[0_174]
22-34	3175-3177	in	abstract[174]	new[174]	_	_
22-35	3178-3180	20	abstract[174]|quantity[175]	new[174]|new[175]	ana	23-1[0_175]
22-36	3181-3182	%	abstract[174]|quantity[175]	new[174]|new[175]	_	_
22-37	3183-3199	fructose-induced	animal[176]	giv[176]	coref	24-25[191_176]
22-38	3200-3201	,	animal[176]	giv[176]	_	_
22-39	3202-3216	salt-sensitive	animal[176]	giv[176]	_	_
22-40	3217-3218	,	animal[176]	giv[176]	_	_
22-41	3219-3231	hypertensive	animal[176]	giv[176]	_	_
22-42	3232-3236	rats	animal[176]	giv[176]	_	_
22-43	3237-3238	.	_	_	_	_

#Text=It has been shown that the ingestion of fructose altered the secretion of hormones that regulate energy balance associated with increased SNA .
23-1	3239-3241	It	quantity	giv	_	_
23-2	3242-3245	has	_	_	_	_
23-3	3246-3250	been	_	_	_	_
23-4	3251-3256	shown	_	_	_	_
23-5	3257-3261	that	_	_	_	_
23-6	3262-3265	the	event[178]	new[178]	_	_
23-7	3266-3275	ingestion	event[178]	new[178]	_	_
23-8	3276-3278	of	event[178]	new[178]	_	_
23-9	3279-3287	fructose	event[178]|substance	new[178]|giv	coref	25-7
23-10	3288-3295	altered	_	_	_	_
23-11	3296-3299	the	event[180]	new[180]	_	_
23-12	3300-3309	secretion	event[180]	new[180]	_	_
23-13	3310-3312	of	event[180]	new[180]	_	_
23-14	3313-3321	hormones	event[180]|substance	new[180]|new	_	_
23-15	3322-3326	that	_	_	_	_
23-16	3327-3335	regulate	_	_	_	_
23-17	3336-3342	energy	abstract|abstract[183]	new|new[183]	_	_
23-18	3343-3350	balance	abstract[183]	new[183]	_	_
23-19	3351-3361	associated	_	_	_	_
23-20	3362-3366	with	_	_	_	_
23-21	3367-3376	increased	abstract[184]	giv[184]	coref	26-23[0_184]
23-22	3377-3380	SNA	abstract[184]	giv[184]	_	_
23-23	3381-3382	.	_	_	_	_

#Text=However , in the current study , although a DGAT1 inhibitor was administered orally to block triglycerides production , sympathoexcitation was not inhibited in fructose-fed rats .
24-1	3383-3390	However	_	_	_	_
24-2	3391-3392	,	_	_	_	_
24-3	3393-3395	in	_	_	_	_
24-4	3396-3399	the	event[185]	giv[185]	coref	34-8[253_185]
24-5	3400-3407	current	event[185]	giv[185]	_	_
24-6	3408-3413	study	event[185]	giv[185]	_	_
24-7	3414-3415	,	_	_	_	_
24-8	3416-3424	although	_	_	_	_
24-9	3425-3426	a	abstract[187]	giv[187]	_	_
24-10	3427-3432	DGAT1	abstract|abstract[187]	giv|giv[187]	_	_
24-11	3433-3442	inhibitor	abstract[187]	giv[187]	_	_
24-12	3443-3446	was	_	_	_	_
24-13	3447-3459	administered	_	_	_	_
24-14	3460-3466	orally	_	_	_	_
24-15	3467-3469	to	_	_	_	_
24-16	3470-3475	block	_	_	_	_
24-17	3476-3489	triglycerides	substance|abstract[189]	giv|new[189]	_	_
24-18	3490-3500	production	abstract[189]	new[189]	_	_
24-19	3501-3502	,	_	_	_	_
24-20	3503-3521	sympathoexcitation	abstract	giv	_	_
24-21	3522-3525	was	_	_	_	_
24-22	3526-3529	not	_	_	_	_
24-23	3530-3539	inhibited	_	_	_	_
24-24	3540-3542	in	_	_	_	_
24-25	3543-3555	fructose-fed	animal[191]	giv[191]	_	_
24-26	3556-3560	rats	animal[191]	giv[191]	_	_
24-27	3561-3562	.	_	_	_	_

#Text=Dos Santos et al indicated that fructose consumption similarly reduced both baroreflex sensitivity and activity .
25-1	3563-3566	Dos	person[192]	new[192]	_	_
25-2	3567-3573	Santos	person[192]	new[192]	_	_
25-3	3574-3576	et	_	_	_	_
25-4	3577-3579	al	_	_	_	_
25-5	3580-3589	indicated	_	_	_	_
25-6	3590-3594	that	_	_	_	_
25-7	3595-3603	fructose	substance|abstract[194]	giv|giv[194]	coref	26-6
25-8	3604-3615	consumption	abstract[194]	giv[194]	_	_
25-9	3616-3625	similarly	_	_	_	_
25-10	3626-3633	reduced	_	_	_	_
25-11	3634-3638	both	abstract[195]|abstract[196]	giv[195]|giv[196]	coref	35-13[0_195]
25-12	3639-3649	baroreflex	abstract[195]|abstract[196]	giv[195]|giv[196]	_	_
25-13	3650-3661	sensitivity	abstract[195]|abstract[196]	giv[195]|giv[196]	_	_
25-14	3662-3665	and	abstract[196]	giv[196]	_	_
25-15	3666-3674	activity	abstract[196]|abstract	giv[196]|new	coref	31-9[214_0]
25-16	3675-3676	.	_	_	_	_

#Text=Our research further indicated that fructose intake may reduce NO levels in the NTS and cause baroreflex dysfunction , which further stimulates SNA and induces the development of high BP (
26-1	3677-3680	Our	person|abstract[199]	giv|new[199]	ana	34-8
26-2	3681-3689	research	abstract[199]	new[199]	_	_
26-3	3690-3697	further	_	_	_	_
26-4	3698-3707	indicated	_	_	_	_
26-5	3708-3712	that	_	_	_	_
26-6	3713-3721	fructose	substance|event[201]	giv|giv[201]	coref	37-4
26-7	3722-3728	intake	event[201]	giv[201]	_	_
26-8	3729-3732	may	_	_	_	_
26-9	3733-3739	reduce	_	_	_	_
26-10	3740-3742	NO	abstract[202]	giv[202]	coref	31-5[212_202]
26-11	3743-3749	levels	abstract[202]	giv[202]	_	_
26-12	3750-3752	in	abstract[202]	giv[202]	_	_
26-13	3753-3756	the	abstract[202]|object[203]	giv[202]|giv[203]	_	_
26-14	3757-3760	NTS	abstract[202]|object[203]	giv[202]|giv[203]	_	_
26-15	3761-3764	and	_	_	_	_
26-16	3765-3770	cause	_	_	_	_
26-17	3771-3781	baroreflex	abstract|abstract[205]	giv|new[205]	_	_
26-18	3782-3793	dysfunction	abstract[205]	new[205]	_	_
26-19	3794-3795	,	_	_	_	_
26-20	3796-3801	which	_	_	_	_
26-21	3802-3809	further	_	_	_	_
26-22	3810-3820	stimulates	_	_	_	_
26-23	3821-3824	SNA	abstract	giv	_	_
26-24	3825-3828	and	_	_	_	_
26-25	3829-3836	induces	_	_	_	_
26-26	3837-3840	the	event[207]	new[207]	_	_
26-27	3841-3852	development	event[207]	new[207]	_	_
26-28	3853-3855	of	event[207]	new[207]	_	_
26-29	3856-3860	high	event[207]|organization[208]	new[207]|giv[208]	coref	31-75[0_208]
26-30	3861-3863	BP	event[207]|organization[208]	new[207]|giv[208]	_	_
26-31	3864-3865	(	_	_	_	_

#Text=Figure 4
27-1	3866-3872	Figure	abstract[209]	new[209]	_	_
27-2	3873-3874	4	abstract[209]	new[209]	_	_

#Text=and
28-1	3875-3878	and	_	_	_	_

#Text=Figure 5
29-1	3879-3885	Figure	abstract[210]	new[210]	_	_
29-2	3886-3887	5	abstract[210]	new[210]	_	_

#Text=) .
30-1	3888-3889	)	_	_	_	_
30-2	3890-3891	.	_	_	_	_

#Text=Generally , anesthetics affect the basal levels of sympathetic nerve activity to regulate blood pressure , which plays an important role in controlling cardiovascular function . Sun et al. indicated that anesthesia attenuated the excitatory response of RSNA and HR to anaphylactic hypotension , while these excitatory responses were attenuated by anesthetics in the order ketamine-xylazine > urethane = pentobarbital . Bencze et al. found that pentobarbital anesthesia had a modest influence on the BP level and its maintenance by the above vasoactive systems .
31-1	3892-3901	Generally	_	_	_	_
31-2	3902-3903	,	_	_	_	_
31-3	3904-3915	anesthetics	substance	new	coref	31-52[226_0]
31-4	3916-3922	affect	_	_	_	_
31-5	3923-3926	the	abstract[212]	giv[212]	_	_
31-6	3927-3932	basal	abstract[212]	giv[212]	_	_
31-7	3933-3939	levels	abstract[212]	giv[212]	_	_
31-8	3940-3942	of	abstract[212]	giv[212]	_	_
31-9	3943-3954	sympathetic	abstract[212]|abstract[214]	giv[212]|giv[214]	coref	33-3[247_214]
31-10	3955-3960	nerve	abstract[212]|abstract|abstract[214]	giv[212]|new|giv[214]	coref	33-4
31-11	3961-3969	activity	abstract[212]|abstract[214]	giv[212]|giv[214]	_	_
31-12	3970-3972	to	_	_	_	_
31-13	3973-3981	regulate	_	_	_	_
31-14	3982-3987	blood	abstract[215]	new[215]	_	_
31-15	3988-3996	pressure	abstract[215]	new[215]	_	_
31-16	3997-3998	,	_	_	_	_
31-17	3999-4004	which	_	_	_	_
31-18	4005-4010	plays	_	_	_	_
31-19	4011-4013	an	abstract[216]	new[216]	_	_
31-20	4014-4023	important	abstract[216]	new[216]	_	_
31-21	4024-4028	role	abstract[216]	new[216]	_	_
31-22	4029-4031	in	_	_	_	_
31-23	4032-4043	controlling	_	_	_	_
31-24	4044-4058	cardiovascular	abstract|abstract[218]	new|new[218]	ana|coref	31-78[0_218]|33-7
31-25	4059-4067	function	abstract[218]	new[218]	_	_
31-26	4068-4069	.	_	_	_	_
31-27	4070-4073	Sun	person	new	_	_
31-28	4074-4076	et	_	_	_	_
31-29	4077-4080	al.	_	_	_	_
31-30	4081-4090	indicated	_	_	_	_
31-31	4091-4095	that	_	_	_	_
31-32	4096-4106	anesthesia	abstract	new	coref	31-67[232_0]
31-33	4107-4117	attenuated	_	_	_	_
31-34	4118-4121	the	abstract[221]	new[221]	_	_
31-35	4122-4132	excitatory	abstract[221]	new[221]	_	_
31-36	4133-4141	response	abstract[221]	new[221]	_	_
31-37	4142-4144	of	abstract[221]	new[221]	_	_
31-38	4145-4149	RSNA	abstract[221]|abstract	new[221]|new	coref	35-10
31-39	4150-4153	and	abstract[221]	new[221]	_	_
31-40	4154-4156	HR	abstract[221]|time[223]	new[221]|new[223]	_	_
31-41	4157-4159	to	abstract[221]|time[223]	new[221]|new[223]	_	_
31-42	4160-4172	anaphylactic	abstract[221]|time[223]|abstract[224]	new[221]|new[223]|new[224]	_	_
31-43	4173-4184	hypotension	abstract[221]|time[223]|abstract[224]	new[221]|new[223]|new[224]	_	_
31-44	4185-4186	,	_	_	_	_
31-45	4187-4192	while	_	_	_	_
31-46	4193-4198	these	abstract[225]	new[225]	_	_
31-47	4199-4209	excitatory	abstract[225]	new[225]	_	_
31-48	4210-4219	responses	abstract[225]	new[225]	_	_
31-49	4220-4224	were	_	_	_	_
31-50	4225-4235	attenuated	_	_	_	_
31-51	4236-4238	by	_	_	_	_
31-52	4239-4250	anesthetics	substance[226]	giv[226]	coref	32-4[0_226]
31-53	4251-4253	in	substance[226]	giv[226]	_	_
31-54	4254-4257	the	substance[226]|abstract[227]|substance[228]	giv[226]|new[227]|new[228]	_	_
31-55	4258-4263	order	substance[226]|abstract[227]|substance[228]	giv[226]|new[227]|new[228]	_	_
31-56	4264-4281	ketamine-xylazine	substance[226]|abstract[227]|substance[228]	giv[226]|new[227]|new[228]	_	_
31-57	4282-4283	>	substance[226]|abstract[227]|substance[228]	giv[226]|new[227]|new[228]	_	_
31-58	4284-4292	urethane	substance[226]|abstract[227]|substance[228]|substance	giv[226]|new[227]|new[228]|new	_	_
31-59	4293-4294	=	_	_	_	_
31-60	4295-4308	pentobarbital	substance	new	_	_
31-61	4309-4310	.	_	_	_	_
31-62	4311-4317	Bencze	person	new	_	_
31-63	4318-4320	et	_	_	_	_
31-64	4321-4324	al.	_	_	_	_
31-65	4325-4330	found	_	_	_	_
31-66	4331-4335	that	_	_	_	_
31-67	4336-4349	pentobarbital	abstract[232]	giv[232]	_	_
31-68	4350-4360	anesthesia	abstract[232]	giv[232]	_	_
31-69	4361-4364	had	_	_	_	_
31-70	4365-4366	a	abstract[233]	new[233]	_	_
31-71	4367-4373	modest	abstract[233]	new[233]	_	_
31-72	4374-4383	influence	abstract[233]	new[233]	_	_
31-73	4384-4386	on	abstract[233]	new[233]	_	_
31-74	4387-4390	the	abstract[233]|abstract[235]	new[233]|giv[235]	_	_
31-75	4391-4393	BP	abstract[233]|organization|abstract[235]	new[233]|giv|giv[235]	coref	35-5
31-76	4394-4399	level	abstract[233]|abstract[235]	new[233]|giv[235]	_	_
31-77	4400-4403	and	abstract[233]	new[233]	_	_
31-78	4404-4407	its	abstract[233]|abstract|abstract[237]	new[233]|giv|new[237]	coref	33-7[249_0]
31-79	4408-4419	maintenance	abstract[233]|abstract[237]	new[233]|new[237]	_	_
31-80	4420-4422	by	abstract[233]|abstract[237]	new[233]|new[237]	_	_
31-81	4423-4426	the	abstract[233]|abstract[237]|abstract[238]	new[233]|new[237]|new[238]	_	_
31-82	4427-4432	above	abstract[233]|abstract[237]|abstract[238]	new[233]|new[237]|new[238]	_	_
31-83	4433-4443	vasoactive	abstract[233]|abstract[237]|abstract[238]	new[233]|new[237]|new[238]	_	_
31-84	4444-4451	systems	abstract[233]|abstract[237]|abstract[238]	new[233]|new[237]|new[238]	_	_
31-85	4452-4453	.	_	_	_	_

#Text=In addition , anesthetics may inhibit the primary area in the baroreceptor reflex pathway of the central nervous system , resulting in attenuation of the baroreceptor reflex .
32-1	4454-4456	In	_	_	_	_
32-2	4457-4465	addition	_	_	_	_
32-3	4466-4467	,	_	_	_	_
32-4	4468-4479	anesthetics	substance	giv	_	_
32-5	4480-4483	may	_	_	_	_
32-6	4484-4491	inhibit	_	_	_	_
32-7	4492-4495	the	abstract[240]	new[240]	_	_
32-8	4496-4503	primary	abstract[240]	new[240]	_	_
32-9	4504-4508	area	abstract[240]	new[240]	_	_
32-10	4509-4511	in	abstract[240]	new[240]	_	_
32-11	4512-4515	the	abstract[240]|abstract[242]	new[240]|new[242]	_	_
32-12	4516-4528	baroreceptor	abstract[240]|abstract[242]	new[240]|new[242]	_	_
32-13	4529-4535	reflex	abstract[240]|place|abstract[242]	new[240]|new|new[242]	coref	9-24
32-14	4536-4543	pathway	abstract[240]|abstract[242]	new[240]|new[242]	_	_
32-15	4544-4546	of	abstract[240]|abstract[242]	new[240]|new[242]	_	_
32-16	4547-4550	the	abstract[240]|abstract[242]|place[243]	new[240]|new[242]|giv[243]	_	_
32-17	4551-4558	central	abstract[240]|abstract[242]|place[243]	new[240]|new[242]|giv[243]	_	_
32-18	4559-4566	nervous	abstract[240]|abstract[242]|place[243]	new[240]|new[242]|giv[243]	_	_
32-19	4567-4573	system	abstract[240]|abstract[242]|place[243]	new[240]|new[242]|giv[243]	_	_
32-20	4574-4575	,	_	_	_	_
32-21	4576-4585	resulting	_	_	_	_
32-22	4586-4588	in	_	_	_	_
32-23	4589-4600	attenuation	event[244]	new[244]	_	_
32-24	4601-4603	of	event[244]	new[244]	_	_
32-25	4604-4607	the	event[244]|place[245]	new[244]|giv[245]	_	_
32-26	4608-4620	baroreceptor	event[244]|place[245]	new[244]|giv[245]	_	_
32-27	4621-4627	reflex	event[244]|place[245]	new[244]|giv[245]	_	_
32-28	4628-4629	.	_	_	_	_

#Text=Therefore , sympathetic nerve activity and cardiovascular function may be affected by the anesthetic .
33-1	4630-4639	Therefore	_	_	_	_
33-2	4640-4641	,	_	_	_	_
33-3	4642-4653	sympathetic	abstract[247]	giv[247]	_	_
33-4	4654-4659	nerve	abstract|abstract[247]	giv|giv[247]	_	_
33-5	4660-4668	activity	abstract[247]	giv[247]	_	_
33-6	4669-4672	and	_	_	_	_
33-7	4673-4687	cardiovascular	abstract|abstract[249]	giv|giv[249]	_	_
33-8	4688-4696	function	abstract[249]	giv[249]	_	_
33-9	4697-4700	may	_	_	_	_
33-10	4701-4703	be	_	_	_	_
33-11	4704-4712	affected	_	_	_	_
33-12	4713-4715	by	_	_	_	_
33-13	4716-4719	the	substance[250]	new[250]	coref	35-18[260_250]
33-14	4720-4730	anesthetic	substance[250]	new[250]	_	_
33-15	4731-4732	.	_	_	_	_

#Text=However , there were some limitations to our study .
34-1	4733-4740	However	_	_	_	_
34-2	4741-4742	,	_	_	_	_
34-3	4743-4748	there	_	_	_	_
34-4	4749-4753	were	_	_	_	_
34-5	4754-4758	some	abstract[251]	new[251]	_	_
34-6	4759-4770	limitations	abstract[251]	new[251]	_	_
34-7	4771-4773	to	abstract[251]	new[251]	_	_
34-8	4774-4777	our	abstract[251]|person|event[253]	new[251]|giv|giv[253]	ana|coref	35-3|36-10[264_253]
34-9	4778-4783	study	abstract[251]|event[253]	new[251]|giv[253]	_	_
34-10	4784-4785	.	_	_	_	_

#Text=First , we measured BP during consciousness , whereas RSNA and baroreflex sensitivity measurements were performed under the anesthetic .
35-1	4786-4791	First	_	_	_	_
35-2	4792-4793	,	_	_	_	_
35-3	4794-4796	we	person	giv	ana	36-3
35-4	4797-4805	measured	_	_	_	_
35-5	4806-4808	BP	abstract	giv	_	_
35-6	4809-4815	during	_	_	_	_
35-7	4816-4829	consciousness	abstract	new	_	_
35-8	4830-4831	,	_	_	_	_
35-9	4832-4839	whereas	_	_	_	_
35-10	4840-4844	RSNA	abstract	giv	_	_
35-11	4845-4848	and	_	_	_	_
35-12	4849-4859	baroreflex	_	_	_	_
35-13	4860-4871	sensitivity	abstract|abstract[259]	giv|new[259]	_	_
35-14	4872-4884	measurements	abstract[259]	new[259]	_	_
35-15	4885-4889	were	_	_	_	_
35-16	4890-4899	performed	_	_	_	_
35-17	4900-4905	under	_	_	_	_
35-18	4906-4909	the	abstract[260]	giv[260]	_	_
35-19	4910-4920	anesthetic	abstract[260]	giv[260]	_	_
35-20	4921-4922	.	_	_	_	_

#Text=Second , our sample size was relatively small and the study used nonparametric methods for analysis .
36-1	4923-4929	Second	_	_	_	_
36-2	4930-4931	,	_	_	_	_
36-3	4932-4935	our	person|abstract[263]	giv|new[263]	_	_
36-4	4936-4942	sample	object|abstract[263]	new|new[263]	_	_
36-5	4943-4947	size	abstract[263]	new[263]	_	_
36-6	4948-4951	was	_	_	_	_
36-7	4952-4962	relatively	_	_	_	_
36-8	4963-4968	small	_	_	_	_
36-9	4969-4972	and	_	_	_	_
36-10	4973-4976	the	event[264]	giv[264]	_	_
36-11	4977-4982	study	event[264]	giv[264]	_	_
36-12	4983-4987	used	_	_	_	_
36-13	4988-5001	nonparametric	abstract[265]	new[265]	_	_
36-14	5002-5009	methods	abstract[265]	new[265]	_	_
36-15	5010-5013	for	_	_	_	_
36-16	5014-5022	analysis	abstract	new	_	_
36-17	5023-5024	.	_	_	_	_

#Text=Third , the fructose group was used as the control group only on day 0 .
37-1	5025-5030	Third	_	_	_	_
37-2	5031-5032	,	_	_	_	_
37-3	5033-5036	the	substance[268]	new[268]	_	_
37-4	5037-5045	fructose	abstract|substance[268]	giv|new[268]	_	_
37-5	5046-5051	group	substance[268]	new[268]	_	_
37-6	5052-5055	was	_	_	_	_
37-7	5056-5060	used	_	_	_	_
37-8	5061-5063	as	_	_	_	_
37-9	5064-5067	the	_	_	_	_
37-10	5068-5075	control	abstract	new	_	_
37-11	5076-5081	group	_	_	_	_
37-12	5082-5086	only	time[270]	new[270]	_	_
37-13	5087-5089	on	time[270]	new[270]	_	_
37-14	5090-5093	day	time[270]	new[270]	_	_
37-15	5094-5095	0	time[270]	new[270]	_	_
37-16	5096-5097	.	_	_	_	_
